These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28036258)

  • 1. Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-κB and Btk.
    Kim JH; Kim WS; Hong JY; Ryu KJ; Kim SJ; Park C
    Oncotarget; 2017 Jan; 8(3):5361-5370. PubMed ID: 28036258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
    Leopizzi M; Mundo L; Messina E; Campolo F; Lazzi S; Angeloni A; Marchese C; Leoncini L; Giordano C; Slack F; Trivedi P; Anastasiadou E
    Blood; 2024 Feb; 143(5):429-443. PubMed ID: 37847858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
    Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
    Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
    Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
    PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.
    Takahashi K; Sivina M; Hoellenriegel J; Oki Y; Hagemeister FB; Fayad L; Romaguera JE; Fowler N; Fanale MA; Kwak LW; Samaniego F; Neelapu S; Xiao L; Huang X; Kantarjian H; Keating MJ; Wierda W; Fu K; Chan WC; Vose JM; O'Brien S; Davis RE; Burger JA
    Br J Haematol; 2015 Dec; 171(5):726-35. PubMed ID: 26358140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways.
    Kato H; Karube K; Yamamoto K; Takizawa J; Tsuzuki S; Yatabe Y; Kanda T; Katayama M; Ozawa Y; Ishitsuka K; Okamoto M; Kinoshita T; Ohshima K; Nakamura S; Morishima Y; Seto M
    Cancer Sci; 2014 May; 105(5):537-44. PubMed ID: 24581222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells.
    Kohlhof H; Hampel F; Hoffmann R; Burtscher H; Weidle UH; Hölzel M; Eick D; Zimber-Strobl U; Strobl LJ
    Blood; 2009 May; 113(22):5506-15. PubMed ID: 19339697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.
    Boccellato F; Anastasiadou E; Rosato P; Kempkes B; Frati L; Faggioni A; Trivedi P
    J Virol; 2007 Mar; 81(5):2274-82. PubMed ID: 17151114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NP9 protein encoded by the human endogenous retrovirus HERV-K(HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2).
    Gross H; Barth S; Pfuhl T; Willnecker V; Spurk A; Gurtsevitch V; Sauter M; Hu B; Noessner E; Mueller-Lantzsch N; Kremmer E; Grässer FA
    Int J Cancer; 2011 Sep; 129(5):1105-15. PubMed ID: 21710493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation.
    Tsai SC; Lin SJ; Lin CJ; Chou YC; Lin JH; Yeh TH; Chen MR; Huang LM; Lu MY; Huang YC; Chen HY; Tsai CH
    J Virol; 2013 Aug; 87(16):9041-52. PubMed ID: 23760235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent downregulation of BTB and CNC homology 2 expression in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Noujima-Harada M; Takata K; Miyata-Takata T; Sakurai H; Igarashi K; Ito E; Nagakita K; Taniguchi K; Ohnishi N; Omote S; Tabata T; Sato Y; Yoshino T
    Cancer Sci; 2017 May; 108(5):1071-1079. PubMed ID: 28256087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
    Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
    J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.
    Pegman PM; Smith SM; D'Souza BN; Loughran ST; Maier S; Kempkes B; Cahill PA; Simmons MJ; Gélinas C; Walls D
    J Virol; 2006 Aug; 80(16):8133-44. PubMed ID: 16873269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus (EBV) provides survival factors to EBV
    Wu L; Ehlin-Henriksson B; Zhou X; Zhu H; Ernberg I; Kis LL; Klein G
    Immunology; 2017 Dec; 152(4):562-573. PubMed ID: 28699226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Europe expression of EBNA2 is associated with poor survival in EBV-positive diffuse large B-cell lymphoma of the elderly.
    Stuhlmann-Laeisz C; Borchert A; Quintanilla-Martinez L; Hoeller S; Tzankov A; Oschlies I; Kreuz M; Trappe R; Klapper W
    Leuk Lymphoma; 2016; 57(1):39-44. PubMed ID: 25899404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in EBNA2 and LMP-1 carboxy terminal region sequences of Epstein-Barr virus type A between the tumors in a multiple cancer patient.
    Higa M; Kinjo T; Miyagi J; Sakumoto N; Iwamasa T; Kishaba M; Sunakawa H
    Pathol Res Pract; 2001; 197(6):401-9. PubMed ID: 11432667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
    Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.